Vamil Divan
Stock Analyst at Guggenheim
(4.56)
# 277
Out of 4,732 analysts
217
Total ratings
62.24%
Success rate
16.17%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Reiterates: Neutral | n/a | $10.86 | - | 5 | Jan 17, 2025 | |
| PFE Pfizer | Maintains: Buy | $35 → $33 | $26.30 | +25.48% | 19 | Dec 11, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $6.66 → $3.1 | $3.68 | -15.76% | 6 | Dec 10, 2024 | |
| ABSI Absci | Reiterates: Buy | $10 | $2.90 | +244.83% | 2 | Dec 3, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $156 → $162 | $147.03 | +10.18% | 11 | Nov 6, 2024 | |
| ABBV AbbVie | Maintains: Buy | $212 → $221 | $171.56 | +28.82% | 22 | Nov 6, 2024 | |
| VERA Vera Therapeutics | Maintains: Buy | $56 → $64 | $33.37 | +91.79% | 4 | Oct 28, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $41 | $18.37 | +123.19% | 7 | Oct 9, 2024 | |
| PROK ProKidney | Initiates: Buy | $6 | $1.66 | +261.45% | 1 | Sep 10, 2024 | |
| INSM Insmed | Maintains: Buy | $70 → $95 | $72.51 | +31.02% | 4 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.58 | - | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $77 | $58.46 | +31.71% | 8 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $7.08 | +182.49% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.37 | +6,855.59% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $1.12 | +703.57% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.96 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $17.57 | +8.14% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $143.26 | -31.59% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.47 | +15.37% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.74 | +264.96% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $91.94 | -46.70% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $725.72 | -50.95% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $3.20 | +87.50% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $37.59 | +309.68% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $10.51 | +42.72% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $23.76 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $21.92 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $81 | $97.92 | -17.28% | 12 | Oct 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $5.01 | +199.40% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $56.29 | +8.37% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.21 | +4,560.63% | 3 | Jan 17, 2018 |
Keros Therapeutics
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.86
Upside: -
Pfizer
Dec 11, 2024
Maintains: Buy
Price Target: $35 → $33
Current: $26.30
Upside: +25.48%
Revance Therapeutics
Dec 10, 2024
Maintains: Neutral
Price Target: $6.66 → $3.1
Current: $3.68
Upside: -15.76%
Absci
Dec 3, 2024
Reiterates: Buy
Price Target: $10
Current: $2.90
Upside: +244.83%
Johnson & Johnson
Nov 6, 2024
Maintains: Neutral
Price Target: $156 → $162
Current: $147.03
Upside: +10.18%
AbbVie
Nov 6, 2024
Maintains: Buy
Price Target: $212 → $221
Current: $171.56
Upside: +28.82%
Vera Therapeutics
Oct 28, 2024
Maintains: Buy
Price Target: $56 → $64
Current: $33.37
Upside: +91.79%
Travere Therapeutics
Oct 9, 2024
Maintains: Buy
Price Target: $23 → $41
Current: $18.37
Upside: +123.19%
ProKidney
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $1.66
Upside: +261.45%
Insmed
Jul 9, 2024
Maintains: Buy
Price Target: $70 → $95
Current: $72.51
Upside: +31.02%
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.58
Upside: -
Apr 23, 2024
Reiterates: Buy
Price Target: $77
Current: $58.46
Upside: +31.71%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $7.08
Upside: +182.49%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.37
Upside: +6,855.59%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.12
Upside: +703.57%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $17.57
Upside: +8.14%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $143.26
Upside: -31.59%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.47
Upside: +15.37%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.74
Upside: +264.96%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $91.94
Upside: -46.70%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $725.72
Upside: -50.95%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $3.20
Upside: +87.50%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $37.59
Upside: +309.68%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $10.51
Upside: +42.72%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $23.76
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $21.92
Upside: -
Oct 11, 2018
Maintains: Outperform
Price Target: $71 → $81
Current: $97.92
Upside: -17.28%
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $5.01
Upside: +199.40%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $56.29
Upside: +8.37%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.21
Upside: +4,560.63%